PF
ALNY icon

Phoenix Financial’s Alnylam Pharmaceuticals ALNY Stock Holding History

Phoenix Financial’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,296
Closed -$229K – 383
2021
Q3 		$229K Buy
+1,296
New +$243K ﹤0.01% 384
2021
Q2 		– Sell
-1,490
Closed -$201K – 301
2021
Q1 		$201K Buy
+1,490
New +$224K ﹤0.01% 389

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Phoenix Financial's ALNY Position: Q4 2021 in Review

Phoenix Financial sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2021, closing a stake of 1,296 shares — an estimated $229K sold.

Phoenix Financial first reported a position in ALNY in Q1 2021 and held it in 2 quarters. The position peaked at $229K in Q3 2021. 435 funds tracked by Wall St. Rank hold ALNY as of Q4 2021.

  • Phoenix Financial reported no remaining Alnylam Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Phoenix Financial sold 1,296 Alnylam Pharmaceuticals shares in Q4 2021, an estimated $229K.
  • Phoenix Financial first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Phoenix Financial's Alnylam Pharmaceuticals position peaked at $229K in Q3 2021.
  • 435 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2021.

Based on Phoenix Financial's 13F filing for Q4 2021, filed 7 Feb 2022.